Trials / Completed
CompletedNCT03679949
Effects of Cannabis on Prescription Drug Abuse Liability and Analgesia
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- New York State Psychiatric Institute · Academic / Other
- Sex
- All
- Age
- 21 Years – 53 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research is to assess the impact of cannabis on the analgesic and abuse-liability effects of a sub-threshold dose of a commonly used analgesic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oxycodone | Oxycodone, 2.5 mg |
| DRUG | Cannabis (THC:CBD = ~ 1:0) | Cannabis with high THC concentration and negligible CBD concentrations |
| DRUG | Cannabis (THC:CBD = ~ 0:1) | Cannabis with high CBD concentration and negligible THC concentrations |
| DRUG | Cannabis (THC:CBD = ~ 1:1) | Cannabis with equivalent CBD and THC concentrations |
| DRUG | Placebo | Cannabis with negligible amounts of THC and CBD 0.0 mg oxycodone |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2022-12-06
- Completion
- 2022-12-06
- First posted
- 2018-09-21
- Last updated
- 2024-12-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03679949. Inclusion in this directory is not an endorsement.